People are always working to improve themselves as the human race. It is out nature to want to be better and to find better ways to do things. This is how we have eradicated diseases that would destroy entire cities as people died of illness they had no cure for. Then as today, this has been accomplished by research into various diseases such as cancer that plague the human race. All researchers want to publish most importantly so that they can add to the body of knowledge.
When publishing; one wants to find a publisher that will not take advantage of them and one that is and can be trusted. Oncotarget is one such publisher. Oncotarget has published some of the most well thought out studies since its inception. For instance, they published a study on triple negative breast cancer by Dr. McDaniel from Alabama. This study is said to have brought us closer to a cure for breast cancer.
They also published a study on the positive effects of natural compounds on cancer cells. The study points out that not only can things like fruits, vegetables, and herbs enhance the effects of radiotherapy and chemotherapy they can also cause kill cancer cells in the right quantities. Although Oncotarget started out publishing cancer research only, they have included aging and genetics research.
Oncotarget is a peer-reviewed journal that publishes research papers with emphasis on cancer research. They have been very successful and because of this have moved into other fields that they previously did not publish. These include cardiology and neurology. The journal’s main aim is to ensure that they can distribute research results quickly and to a wide audience.
The journal was established in the year 2010 and is a member of The Wellcome Trust List of Compliant Publishers. It is a weekly publication that is free on the internet. Oncortaget has two editors-in-chief that are, Andrei V. Gudkov from the Roswell Park Cancer Center and Mikhail Blagosklonny. They work with an editorial board of health professional, and scientists specialized in various fields. The journal’s impact factor is 5.168 which points to its reliability by researchers. Oncotarget is also available on Dove Press.